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Abstract: Cancer is the second cause of death in Turkey and the frequency of cancer deaths increased from 12% in 2002 to 21% in
2009 ( Özkan et al., 2013). To win the war on cancer, we certainly need to apply well-planned prevention policies, given that it is caused
mostly by environmental factors, and to develop more effective therapies. To achieve a cure for the disease, it is crucial to understand
the cellular and molecular mechanisms leading to cancer and to therapeutically target all the factors playing a role in the initiation,
progression, maintenance, and relapse of the disease, preferably in the form of personalized therapy. One of the biggest challenges faced
during the diagnosis and treatment of tumors, especially those arising from tissues composed of heterogeneous cell populations such
as hematopoietic tissues, is to find the cell of origin or the cancer-initiating cell. Knowing the cell of origin can help in dissecting the
normal features of the target cell from its abnormal cancerous form; moreover, this knowledge provides insight into the early events
leading to a malignant transformation and eventually shapes the treatment protocols. Initial and ongoing studies in leukemia elegantly
showed how to identify the cell of origin (or the stem cells of cancers) and how to calculate their frequency and evolution during disease
progression. This minireview summarizes the current view on cancer stem cells, and particularly leukemic stem cells, and their potential
role in the initiation, maintenance, and therapy resistance of cancer.
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1. Introduction
Cancer(s) could be considered as a group of complicated
diseases that can arise from many different cell types in
our body with peculiar underlying molecular pathways
that act in a cell context-dependent manner. Adding to the
complexity, the same cell can also become cancerous via
the acquisition of different epigenetic or genetic alterations,
which are prone to change or accumulate more during the
progression and treatment of the disease. Although cancer
originates from a single cell that abnormally proliferates
and clonally expands, examination of tumor tissues shows
heterogeneous cell populations, exhibiting different levels
of differentiation and morphology under the microscope.
Based on this observation, scientists hypothesized decades
ago that, similar to the development of normal tissues,
cancerous tissues are probably also hierarchically organized
and cancer arises from cancer stem cells (CSCs), which are
possibly responsible for the initiation, maintenance, and
relapse of tumors (reviewed in Dick, 2008; Magee et al.,
2012). Recent research on CSCs provided clear evidence
for the existence of cancers (like acute myeloid leukemia
(AML)) that fit in this CSC model (Eppert et al., 2011).
Currently, it is widely accepted that CSCs are responsible
for therapy resistance and only therapies that effectively
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eliminate CSCs would result in a cure in cancers that
follow the CSC model.
2. Normal and leukemic hematopoiesis
Hematopoiesis (blood cell formation) is a process that
provides the daily blood needs of our body and is initiated
with the division of hematopoietic stem cells (HSCs),
giving rise to two types of daugther cells: one daughter cell
retains its HSC identity, whereas the other daughter cell
begins to differentiate. HSCs are the common ancestors
of all types of blood cells, and based on their self-renewal
activity, they can be divided into two subsets: 1) long-term
HSCs (LT-HSCs), which are highly self-renewing cells that
are competent to reconstitute an animal for its entire life
span; and 2) short-term HSCs (ST-HSCs) that reconstitute
the animal for a limited period. The division of HSCs gives
rise to nonself-renewing multipotent progenitors (MPP),
a progeny with more limited differentiation potential, and
finally to all types of functionally mature hematopoietic
cells (Kondo et al., 2003; Passegue et al., 2003). Cell surface
markers are widely used to identify the lineage or stage of
maturation of certain hematopoietic cells. For instance, all
HSC activity in the mouse is contained within the c-Kit+/
Sca-1+, lineage markerlow/–(Linlow/–) component, while in the
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human it is within the CD34+/CD38– component, which
constitutes less than 1% of the bone marrow, and most of
these cells represent ST-HSCs, multilineage progenitors,
or lineage-committed progenitors (Uchida and Weissman,
1992; Osawa et al., 1996; Christensen and Weissman, 2001;
Rieger and Schroeder, 2012). In addition to the cell surface
marker phenotype, HSCs can also be identified as a side
population (SP) after staining with the DNA-binding dye
Hoechst-33342 and selecting the unstained cells using a
fluorescence activated cell sorter (FACS) (Goodell et al.,
1996). The SP profile is formed by Hoechst-33342 dye
efflux activity, which is a consequence of P-glycoprotein/
ABC transporter (Bcrp1/ABCG2) expression on the
surface of HSCs (Goodell et al., 1996; Kim et al., 2002).
The SP accounts for 0.07% to 0.1% of murine bone marrow
and represents at least a 1000-fold enrichment of LT-HSCs
(Goodell et al., 1996).
Hematopoiesis is normally regulated by homeostatic
mechanisms that control the production of blood cells
according to the requirements of the organism. The
decision between self-renewal and lineage commitment
of the HSCs is mainly regulated by coordinated activity
of extracellular signals and differential expression of
key transcription factors. Leukemia results from clonal
expansion of immature hematopoietic cells and an
altered capacity to differentiate into functional cells due
to accumulating genetic and epigenetic modifications
that affect both self-renewal and differentiation (Sawyers
et al., 1991; Passegue et al., 2003; Rosmarin et al., 2005).
The presence of leukemic stem cells (LSCs) was proposed
over 40 years ago based on the findings that over 90%
of the leukemic cells in patients with AML or acute
lymphoblastic leukemia (ALL) were postmitotic and the
dividing leukemic cell fraction contained both fast (within
24 h) and slow cycling (between weeks to months) cell
populations (Clarkson, 1969) (reviewed in Dick, 2008).
The conclusion drawn from that study was that the slow
cycling population that showed different morphological
features probably generated the fast cycling leukemic cells,
a process resembling normal hematopoiesis, and the slow
cycling cells were LSCs that were possibly responsible for
the initiation of leukemia, resistance to antiproliferative
chemotherapy agents, and relapse. In the following years,
the development of new technologies, and especially of the
FACS, allowed the purification of different cell populations
with high viability and specificity and fostered cancer
stem cell research. The isolation and xenotransplantation
of different cell fractions of AML bone marrow samples
showed the first experimental evidence for the existence of
LSCs in CD34+/CD38– fractions that were able to undergo
self-renewal and generate leukemia in xenografts, a feature
that distinguished them from the bulk of leukemic cells that
did not retain this capacity (Bonnet and Dick, 1997; Hope

et al., 2004). These results indicated that AML possibly
arose from HSCs with leukemic mutations, and like
normal hematopoiesis, AML was organized hierarchically
and was initiated and sustained by rare LSCs, supporting
the CSC model that was proposed decades ago.
3. Identifying the cell of origin in leukemia
Initially HSCs were thought to be the origin of AML based
on the above-mentioned findings that leukemia-initiating
cells, or LSCs, carry CD34+/CD38– surface proteins. A
recent study has provided additional data about the origin
of LSCs: when the bone marrow samples of AML patients
were separated into different cellular fractions by using
an FACS and transplanted into more immunodeficient
mice that were used in previous experiments, it was
shown that in some AML patients LSCs were found in
the undifferentiated (CD34+/CD38–) stem cell/progenitor
cell fraction, but in some other patients LSCs existed in
both undifferentiated and more differentiated (CD34+/
CD38+, CD34–/CD38–, CD34–/CD38+) cell fractions,
emphasizing the heterogeneity of patient samples (Eppert
et al., 2011). These findings are consistent with previous
results obtained from different experimental models
showing that both HSCs and developmentally more
restricted progenitors are capable of transforming into
LSCs as a result of accumulating mutations (Blair et al.,
1998; Higuchi et al., 2002; Cozzio et al., 2003). It was
proposed that since HSCs already have self-renewal ability,
the initial mutations influencing their survival, apoptosis,
or differentiation pathways may induce leukemogenic or
preleukemic activity in HSCs, whereas in progenitor cells
lacking this ability the initial mutations serve to restore
their self-renewal activity, allow enough time for the cells
to accumulate subsequent mutations, and could lead to
a fully transformed LSC (Gilliland et al., 2004). Today
it is clear that mutations influence the leukemogenic
process depending on the order of acquisition and the
cellular context in which they occur. In support of this
view, comprehensive mutation analysis of patient samples
showed that leukemic cells carry heterogeneous mutations
and some of the mutations existing in HSCs at diagnosis
persist during long-term remissions and relapses. Such
examples include the AML1-ETO fusion (Miyamoto et
al., 2000) and DNMT3A mutations (Shlush et al., 2014)
in AML patients, and the BCR-ABL oncogene found in
chronic myeloid leukemia (Chu et al., 2011). On the other
hand, some other mutations, like the NPM1 mutations
found in AML (Shlush et al., 2014), mostly exist in bulk
leukemic cells, but not in the HSCs of the patient, and
disappear following therapy, suggesting that during disease
progression this type of mutations are incurred in bulk
leukemic cells that are sensitive to therapy. Furthermore,
analysis of monozygotic twins showed the presence of ALL
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specific TEL-AML1 fusion proteins in the nonleukemic
twins’ HSCs, which are capable of differentiation
into mature cells (Hong et al., 2008). Consistently,
xenotransplantation of TEL-AML1-transduced cord blood
cells generate a preleukemic condition but not leukemia.
Altogether, these data provide experimental evidences
that some mutations occurring in HSCs generate normally
differentiating preleukemic HSCs, and later in time the
more mature progeny of these preleukemic cells incur
serial transforming mutations, resulting in leukemia.
In conclusion, several possibilities exist about the origin
of LSCs. LSCs might originate from a normal HSC that

incurs serial leukemic mutations, or alternatively, initial
mutations might occur in HSCs and generate preleukemic
HSCs, whereas an LSC transformation arises in the
committed progenitors upon accumulation of additional
mutations. It is also possible that the initial leukemic
mutations might occur in committed progenitors, which
then gain LSC character (Figure 1).
4. Frequency of LSCs
Xenotransplantation into immunocompromised mice is
the currently accepted in vivo assay that determines the
frequency and functionality of human LSCs. Although

.

.

Figure 1. The cell of origin in leukemia. A preleukemic mutation in a HSC, followed by additional leukemic mutations in a committed
progenitor (upper panel) can result in leukemia. Alternatively, a leukemic mutation can occur in a committed progenitor without
affecting the HSCs, causing leukemic transformation (lower panel).
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the frequency of LSCs in the initial xenotransplant studies
was 0.2–100/106 in AML patients (Bonnet and Dick,
1997), subsequent data from mouse models of AML
or B- and T-cell lymphoma showed that the frequency
of LSCs could be as high as 1/10 when leukemic mouse
cells are transplanted into histocompatible mice (Kelly
et al., 2007). Similarly, a B-cell acute lymphoblastic
leukemia mouse model generated in Arf–/– mice by
introducing the BCR-ABL oncogene into progenitors in
the bone marrow, showed that about 50% of leukemic
cells are able to induce leukemia upon transplantation
into healthy syngeneic mice (Williams et al., 2007).
These studies suggested that xenotransplantation assays
might underestimate the frequency of LSCs due to
low engraftment ability of some human cells in the
transplanted host environment. Xenotransplantation
studies performed with primary human melanoma cells
supported this notion, showing that transplantation of
the cells into a more immunocompromised mouse model,
lacking B-cells, T-cells, and natural killer cells, increased
the detected tumorigenic cell percentage from one in a
million (Schatton et al., 2008) to one in four (Quintana
et al., 2008). Therefore, experimental limitations such as
the absence of cross-species reactivity of cytokines and
other microenvironmental factors in the host used for
xenotransplantation, or intrinsic factors of transplanted
cells could negatively affect the outcome of LSC-frequency
assays. It is important to note that, when Eppert et al.
(2011) used the best available immunodeficient mice
for xenotransplantation assay in their recent study, the
frequency of LSCs was still low in the analyzed AML
patients, suggesting that leukemia propagating cells (or
LSCs) are rare in certain types of leukemia. The current
data suggest that the frequency of cancer-initiating cells
differ between cancers, and although the CSC model is
valid for some types of leukemia, it may not be a universal
model covering all cancers.
5. Evolution of LSCs
Another important aspect of LSCs is the clonal evolution
generated by a stepwise accumulation of mutations.
During this process, the initial LSC clone gives rise to the
production of subclones carrying different combinations
of mutations in addition to the initial driver mutation or
mutations. Clonal evolution leading to clonal diversity
occurs both, during the progression of the disease and
following therapy (Greaves, 2010; Grove and Vassiliou,
2014). Mutation analysis of pediatric ALL patient
samples using single cell sequencing technology reflects
the complexity of such subclonal diversity, showing the
existence of about 4000 genetically different subclones in
one patient at a certain disease stage (Gawad et al., 2014).
Current data from leukemia patients suggest that the

dominant clone or clones with proliferative and survival
advantage can differ in time due to the selective pressures
generated by environmental factors and/or therapy. In
other words, a dormant therapy-resistant subclone that
could not compete with the dominant clone or clones
at the beginning of the disease might become dominant
after eradication of the main clones by therapy, resulting
in relapse and therapy resistance (Greaves, 2010). Making
the situation more complicated, cells within a subclone
carrying the same mutations could have different
functional properties such as different engraftment abilities
in xenotransplantation assays (Kreso et al., 2013). This
suggests that epigenetic and environmental factors further
increase clonal heterogeneity and generate functionally
distinct populations within a genetically defined subclone
(Greaves, 2010; Grove and Vassiliou, 2014; Lang et al.,
2015).
6. Examples of experimental approaches used in LSC
research
One of the widely used approaches to discover leukemiainitiating cells is the generation of stable overexpression
of a known oncogene in different cellular fractions
(such as HSCs, common myeloid progenitors (CMP),
and granulocyte macrophage progenitors (GMP)) of the
bone marrow and monitoring the disease occurrence
after transplanting these transduced cells into mice. Bone
marrow cell fractions could be isolated based on the
known specific surface marker expression using a FACS
(Seita and Weissman, 2010) and the overexpression of the
oncogene could be managed by retroviral transduction,
which should be achieved in a very short period of cell
culture in the presence of cytokines supporting the
growth of immature hematopoietic cells, followed by an
immediate transplantation into mice. Both mouse and
human hematopoietic cells could be examined using
this approach. For instance, the Meningioma 1 (MN1)
gene is a myeloid oncogene that promotes AML when
overexpressed in c-Kit+/Sca-1+/Lin– primary mouse
hematopoietic cells (a cellular compartment containing
both HSCs and immature progenitors) in mouse models
(Carella et al., 2007; Heuser et al., 2007). We have recently
shown that the overexpression of MN1 in c-Kit+/Sca-1+/
Lin– specifically increases the frequency of downstream
CMP cells in vitro (Kandilci et al., 2013), which suggests
that in MN1-induced AML the leukemia-initiating cells
are possibly CMP cells. Clear experimental evidence for
this hypothesis is provided by Heuser et al. (2011) when
they sorted the HSC, CMP, and GMP populations and then
introduced the ectopic MN1 into these sorted cells using
a retrovirus. That study clearly showed that only MN1transduced mouse CMP cells were capable of leukemic
transformation when transplanted into mice, therefore
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identifying the CMP cells as the leukemia initiating cells
(or CSCs) in MN1-induced leukemia. That study also
showed that HSCs or GMP cells lacked this property
when they overexpressed MN1, once more emphasizing
the importance of cooperation between the oncogene and
the cellular context in which it is overexpressed in the
development of cancer/leukemia.
7. Conclusion
All the features of LSCs and bulk leukemic cells
highlighted above indicate that, similar to other cancers,
leukemia is not a uniform disease and fighting leukemia
actually requires the treatment of several different types
of leukemia in one patient (Lang et al., 2015). Current
data from cancer research suggest that detailed serial
analysis of patient samples should be performed prior to
and following therapy to reveal the molecular structure of
the leukemic clones at diagnosis, remission, and relapse.
Advances in single cell sequencing technology, such as
Drop-Seq analysis that currently costs 6 cents per cell

in the United States (Macosko et al., 2015), increase
the feasibility of such screens. Following detailed serial
analysis of patient samples, sequential treatment protocols
with different targeted drugs at different disease stages
should be applied in a patient specific manner to eradicate
LSCs. In combination with this type of targeted therapies,
it is also important to design and use therapies eradicating
the bulk leukemic (or cancer) cells. This is obviously not
an easy task and, in addition to a good infrastructure run
by experts, it requires the cooperation of well-educated
personnel in multiple disciplines, including but not
limited to medicine, molecular biology, bioengineering,
bioinformatics, and pharmaceuticals.
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